CIRC
(Plasmid
#186343)
-
PurposeContains VEGFA exon 7 and part of intronic flanking regions enabling expression of hsa_circ_0076611 (circVEGF)
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 186343 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepcDNA3.1
-
Backbone manufacturerinvitrogen
- Backbone size w/o insert (bp) 5428
- Total vector size (bp) 6177
-
Modifications to backboneHind III to Xho I removal from MCS during cloning
-
Vector typeMammalian Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameVEGFA
-
Alt nameVEGF
-
SpeciesH. sapiens (human)
-
Insert Size (bp)749
-
GenBank IDNM_001025366.3 NM_001025366.3
-
Entrez GeneVEGFA (a.k.a. L-VEGF, MVCD1, VEGF, VPF)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site HindIII (not destroyed)
- 3′ cloning site XhoI (not destroyed)
- 5′ sequencing primer T7 (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
CIRC was a gift from Giovanni Blandino (Addgene plasmid # 186343 ; http://n2t.net/addgene:186343 ; RRID:Addgene_186343) -
For your References section:
MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer. Turco C, Esposito G, Iaiza A, Goeman F, Benedetti A, Gallo E, Daralioti T, Perracchio L, Sacconi A, Pasanisi P, Muti P, Pulito C, Strano S, Ianniello Z, Fatica A, Forcato M, Fazi F, Blandino G, Fontemaggi G. Commun Biol. 2022 Jun 16;5(1):598. doi: 10.1038/s42003-022-03539-x. 10.1038/s42003-022-03539-x PubMed 35710947